Asian Markets Rally on Iran Ceasefire Hopes as US-Iran Tensions Simmer 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Oil Crisis Escalates: Trump Threatens Iran as Strait of Hormuz Closure Pushes Prices Above $110 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
European Stocks Hold Steady as Iran Ceasefire Deadline Looms 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Gold Prices Slip in Asia as Iran Strait Deadline Looms 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Citigroup Delays Fed Rate Cut Forecast Amid Strong Jobs Data and Inflation Concerns 
Asian Markets Hold Steady Ahead of Trump's Iran Deadline as Oil Tops $110 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Global LNG Exports Drop 4% in Q1 2026 as Qatar Shutdown Reshapes Energy Markets 
Sterling Slides as Dollar Holds Firm Amid U.S.-Iran Tensions 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
GSK, a British pharmaceutical and biotech firm that was formerly known as Glaxo Smith Kline plc, announced that it had hired Julie Brown to be its new chief financial officer. The company said on Monday, Sept. 26, that the executive would formally join GSK next week.
According to Sky News, the move to recruit Brown is a strategy to form an all-female team of executives. It was reported that the newly-recruited CFO was poached by GSK from the Burberry Group PLC fashion company.
Brown will be replacing Iain Mackay, who is set to retire. He has been serving as GSK’s finance chief since 2019. The formation of an all-female team is very rare in the business, but the company is aiming for this with the recruitment of Brown.
Reuters reported that Brown is set to step down in April 2023 from Burberry after serving for more than five years as its CFO. She is a 60-year-old British woman who started working at the said fashion house in 2017. Prior to this, she worked at Smith & Nephew's medical device products manufacturing firm.
She also held an executive job role in AstraZeneca as interim group CFO and was appointed to senior roles at some of GSK’s rival companies. In addition, she was a non-executive director of Roche Holding Swiss healthcare group, but she is likely to step down after accepting the CFO role at GSK.
“I want to thank Iain for all he’s done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance,” GSK’s chief executive officer, Emma Walmsley, said in a press release. “I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector.”
The CEO added, “We also share a strong passion for people development, diversity, inclusion and sustainability. I am looking forward to working together to deliver progress for patients, shareholders and our people.”
